Instil Bio, Inc. financial data

Symbol
TIL on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
3963 Maple Avenue, Suite 350, Dallas, TX
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.47K % +69.2%
Debt-to-equity 47.2 % +39.1%
Return On Equity -55.6 % -3.33%
Return On Assets -37.8 % +5.98%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 6.5M shares -95%
Common Stock, Shares, Outstanding 6.5M shares -95%
Entity Public Float 34.4M USD -88%
Common Stock, Value, Issued 0 USD
Weighted Average Number of Shares Outstanding, Basic 6.5M shares 0%
Weighted Average Number of Shares Outstanding, Diluted 6.5M shares 0%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 20.7M USD -76.9%
General and Administrative Expense 45.9M USD -15.9%
Operating Income (Loss) -118M USD +38.9%
Nonoperating Income (Expense) -2.28M USD -256%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -156M USD +30.7%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -120M USD +35.6%
Earnings Per Share, Basic -18.4 USD/shares +59.3%
Earnings Per Share, Diluted -18.4 USD/shares +59.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 6.78M USD -68.8%
Marketable Securities, Current 141M USD -35%
Assets, Current 155M USD -29.8%
Property, Plant and Equipment, Net 133M USD -26.6%
Operating Lease, Right-of-Use Asset 1.71M USD -45.9%
Goodwill 0 USD -100%
Other Assets, Noncurrent 581K USD -81.3%
Assets 294M USD -27.9%
Accounts Payable, Current 1.22M USD -43.7%
Employee-related Liabilities, Current 2M USD -22.2%
Liabilities, Current 10.3M USD -44%
Deferred Income Tax Liabilities, Net 0 USD -100%
Operating Lease, Liability, Noncurrent 2.02M USD -45.4%
Other Liabilities, Noncurrent 8K USD -95.1%
Liabilities 99.3M USD -11.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax -627K USD +21.1%
Retained Earnings (Accumulated Deficit) -620M USD -23.9%
Stockholders' Equity Attributable to Parent 195M USD -34.2%
Liabilities and Equity 294M USD -27.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -14.4M USD +58.5%
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Net Cash Provided by (Used in) Investing Activities 9.24M USD -36.4%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 6.5M shares -95%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 6.78M USD -70.4%
Interest Paid, Excluding Capitalized Interest, Operating Activities 1.73M USD +17.1%
Deferred Tax Assets, Valuation Allowance 127M USD +46.8%
Deferred Tax Assets, Gross 127M USD +44.3%
Operating Lease, Liability 3.69M USD -33.9%
Depreciation 4M USD -42%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -119M USD +35.8%
Lessee, Operating Lease, Liability, to be Paid 3.96M USD -35.3%
Property, Plant and Equipment, Gross 138M USD -25.9%
Operating Lease, Liability, Current 1.67M USD -11.4%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.22M USD -32.1%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.82M USD -8.41%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 271K USD -49.4%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.82M USD +43.1%
Deferred Tax Assets, Operating Loss Carryforwards 88.4M USD +51.8%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 2.34M USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.22M USD -4.17%
Operating Lease, Payments 2.25M USD -18.2%
Additional Paid in Capital 816M USD +2.25%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 993K USD -44.1%
Deferred Tax Assets, Net of Valuation Allowance 0 USD -100%
Share-based Payment Arrangement, Expense 17.9M USD -24%
Interest Expense 6.55M USD +160%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%